Analgesics and Antipyretics, 2. Nonsteroidal Anti-inflammatory Drugs
Elmar Friderichs,
Thomas Christoph,
Helmut Buschmann,
Elmar Friderichs
Grünenthal GmbH, Center of Research, Aachen, Germany
Search for more papers by this authorThomas Christoph
Grünenthal GmbH, Center of Research, Aachen, Germany
Search for more papers by this authorHelmut Buschmann
Laboratorios Dr. Esteve S.A., Barcelona, Spain
Search for more papers by this authorElmar Friderichs,
Thomas Christoph,
Helmut Buschmann,
Elmar Friderichs
Grünenthal GmbH, Center of Research, Aachen, Germany
Search for more papers by this authorThomas Christoph
Grünenthal GmbH, Center of Research, Aachen, Germany
Search for more papers by this authorHelmut Buschmann
Laboratorios Dr. Esteve S.A., Barcelona, Spain
Search for more papers by this authorFirst published: 15 October 2011
Abstract
The article contains sections titled:
1. |
Introduction |
2. |
Salicylates |
3. |
Para-Aminophenol Derivatives |
4. |
Anthranilates |
5. |
Arylacetic Acids |
6. |
Arylpropionic Acids |
7. |
Pyrazolinone Derivatives |
8. |
Acidic Enolic Compounds |
8.1. |
Pyrazolidine-3,5-diones |
8.2. |
Arylsulfonamides (Oxicames) |
9. |
Other Structures |
10. |
COX-2 Inhibitors |
10.1. |
Nonselective COXC-2 Inhibitors |
10.2. |
Selective COX-2 Inhibitors (Coxibs) |
General References
- 1 J. G. Hardman (eds.) et al.: Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed., McGraw Hill, New York 1995, pp. 521–555, 557–600, 617–657.
- 2 J. E. F. Reynolds (eds.) et al.: Martindale The Extra Pharmacopoeia, 31st ed., The Royal Pharmaceutical Society, London 1996.
- 3 A. Herz (ed.): Handbook of Experimental Pharmacology, vol. 104/I, Opioids I., vol. 104/II, Opioids II, Springer Verlag, Berlin 1993.
- 4 T. Dickenson, J. Besson (eds.): Handbook of Experimental Pharmacology. The Pharmacology of Pain, vol. 130, Springer Verlag, Berlin 1997.
- 5 M. Zenz, I. Jurna (eds.): Lehrbuch der Schmerztherapie. Grundlage, Theorie und Praxis für Aus- und Weiterbildung. Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart 1993.
- 6 J. J. Bonica (ed.): The Management of Pain, 2nd ed., Lea & Febiger, 1990.
- 7 S. Budavari (ed.): The Merck Index, 12th ed., Merck & Co. Inc., 1996.
- 8 P. D. Wall, R. Melzack (eds.): Textbook of Pain, 3rd ed., Churchill Livingstone, New York 1994.
- 9 J. R. Vane et al., “Cyclooxygenases 1 and 2,” Annu. Rev. Pharmacol. Toxicol. 38 (1998) 97–120.
- 10 C. J. Hawkey: “Cox-2 Inhibitors”, Lancet 353 (1999) 307–314.
Specific References
- 11 J. R. Vane et al., Ann. Rev. Pharmacol. Toxicol. 38 (1998) 97–120.
- 12 K. L. Pierce et al., TIPS 16 (1995) 253–256.
- 13 C. D. Funk, et al., FASEB J. 5 (1991) 2304–2312.
- 14 D. A. Kujubu et al., J. Biol. Chem. 266 (1991) 12866–72.
- 15 T. Hla, K. Neilson, Proc. Natl. Acad. Sci. U S A. 89 (1992) 7384–8.
- 16 M. K. O'Banion, et al., Proc. Natl. Acad. Sci. U S A. 89 (1992) 4888–4892.
- 17 R. Langenbach et al., Ann. N. Y. Acad. Sci. 889 (1999) 52–61.
- 18 S. G. Morham et al., Cell 83 (1995) 473–482.
- 19 J. E. Dinchuk et al., Nature 378 (1995) 406–409.
- 20 D. Picot et al., Nature 367 (1994) 243–249.
- 21 J. R. Kiefer et al., Nature 405 (2000) 97–101.
- 22 J. R. Vane et al., Annu. Rev. Pharmacol. Toxicol. 38 (1998) 97–120.
- 23 J. Berg et al., J. Pharmacol. Toxicol. Meth. 37 (1997) 179–186.
- 24 A. Graul et al., Drugs Future 22 (1997) 711–714.
- 25 L. J. Crofford et al., J. Clin. Invest. 93 (1994) 1095–101.
- 26 H. Sawaoka et al., Prostaglandins Leukot. Essent. Fatty Acids 59 (1998) 313–316.
- 27 C. J. McCarthy et al., Am. J. Gastroenterol. 94 (1999) 1218–1223.
- 28 R. Langenbach et al., Ann. N.Y. Acad. Sci. 889 (1999) 52–61.
- 29 L. J. Crofford, Curr. Pharm. Des. 17 (2000) 1725–36.
- 30 C. Bombardier et al., N. Engl. J. Med. 343 (2000) 1520–1528.
- 31 R. S. Bresalier et al., N. Engl. J .Med. 352 (2005) 1092–1102.
- 32 S. D. Solomon et al., N. Engl. J. Med. 352 (2005) 1071–1180.
- 33 N. A. Nussmeier et al., N. Engl. J. Med. 352 (2005) 1081–1091.
- 34 B. F. McAdam et al., Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 272–277.
- 35 X. Leval et al., Curr. Med. Chem. 9 (2002) 941–962.
- 36 M. Inagaki et al., J. Med. Chem. 43 (2000) 2040–2048.
- 37 S. Tries et al., Inflamm. Res. 51 (2002) 135–143.
- 38 S. Laufer et al., Arzneimittelforschung 44 (1994) 1329–1333.
- 39 B. Chin, J. Wallace, Curr. Opin. Investig. Drugs 1 (1999) 148–152.
- 40 C. Pisano et al., Dig. Dis. Sci. 44 (1999) 713–724.
- 41 S. Fiorucci, E. Antonelli, Curr. Top. Med. Chem. 5 (2005) 487–492.
- 42 R. Scatena, Curr. Opin. Investig. Drugs 5 (2004) 551–556.
- 43 J. L. Wallace et al., Am. J. Physiol. Gastrointest. Liver Physiol. 286 (2004) G76–81.
- 44 C. Patrono, N. Engl. J. Med. 330 (1994) 1287–1294.
- 45 Patrignani et al., Br. J. Pharmacol. 118 (1996) 1285–1293.
- 46 R. G. Kurumbail et al., Nature 384 (1996) 644–648.
- 47 A. S. Kalgutkar et al. Science 280 (1998) 1268–1270.
- 48 A. Kleemann, J. Engel, B. Kutscher, D. Reichert: Pharmaceutical Substances, Synthesis, Patents, Applications, Thieme, Stuttgart – New York, 1999 (available in print and CD-ROM).
- 49 N. Kuhnert, Chem. Unserer Zeit 33 (1999) 213–220.
- 50 Am. J. Med. 74 (1983) no. 6A, 1–109.
- 51 I. Tegeder et al., FASEB J. 15 (2001) 2057–2072.
- 52 C. J. Needs, P. M. Brooks, Clin. Pharmacokinet. 10 (1985) 164–177.
- 53 R. J. Waldmann et al., JAMA 247 (1982) 3089–3094.
- 54 Merck & Co., US 4 225 730, 1980, (H. Jones, R. Houser.
- 55 For alternative synthesis: US 3 992 495, (Merck & Co.).
- 56 For alternative synthesis: US 4 131 618, (Merck & Co.).
- 57 J. Hannah et al., J. Med. Chem. 21 (1978) 1093.
- 58
E. Arrigoni-Martelli,
Drugs Future
3
(1978)
28–33.
10.1358/dof.1978.003.01.277269 Google Scholar
- 59 J. Hannah et al., J. Med. Chem. 21 (1978) 1093–1100.
- 60 M. Cotton, R. A. Hux, Anal. Profiles Drug Subst. 14 (1985) 491–526.
- 61 J.M. Young et al., Inflamm Res. 45 (1996) 246–253.
- 62 Lunbeck, GB 656 746, 1948.
- 63 D. S. Hoffenberg, C. R. Hauser, J. Org. Chem. 20 (1955) 1496–1500.
- 64 Warner-Lambert, US 2 998 450, 1961, (G. Wilbert, J. De Angelis).
- 65 B. Ameer et al., Ann. Int. Med. 87 (1977) 202–209.
- 66 D. A. Willoughby et al., Lancet 355 (2000) 646–648.
- 67 P. Kirkpatrick, Nature Reviews Drug Discovery 4 (2005) 883.
- 68 E. D. Hogestatt et al., J. Biol. Chem. 36 (2005) 31405–31412.
- 69 R. K. Lewis, F. P. Paloucek, Clin. Pharm. 10 (1991) 765–774.
- 70 M. Depre et al., Fundam. Clin.Pharmacol. 6 (1992) 259–262.
- 71 U. C. Dubach et al., N. Engl. J. Med. 308 (1983) 357–362.
- 72 K. H. Boltze, H. Kreisfeld, Arzneim.-Forsch./Drug Res. 27 (1977) no. 1, 1300–1312.
- 73 R. Coletta et al., Int. J. Clin. Pharmacol. Res. 8 (1988) 295–298.
- 74 Parke Davis, FR 1 341 M, 1961.
- 75 R. B. Moffett, B. D. Aspergen, J. Am. Chem. Soc. 82 (1960) 1605.
- 76 S. Ravi et al., Postgrad. Med. J. 62 (1986) 773–776.
- 77 H. Gögelein et al., FEBS Lett. 268 (1990) 79–82.
- 78 M. M. White et al., Mol. Pharmacol. 37 (1990) 720–724.
- 79 L. Sorbera et al., Drugs of the Future 26 (2001) 133–140.
- 80 G. J. Grover et al., J. Pharmacol. Exp. Ther. 269 (1994) 536–540.
- 81 Y. T. Lee, Q. Wang, Eur. J. Pharmacol. 378 (1999) 349–356.
- 82 Parke Davis, US 3 313 848, 1967; DE 1 149 015, 1961.
- 83 P. F. Juby et al., J. Med. Chem. 11 (1968) 111–117.
- 84
E. Arrigoni-Martelli,
Drugs Future
3
(1978)
307–310.
10.1358/dof.1978.003.04.277278 Google Scholar
- 85 J. R. McLean, M. I. Geuckman, Arzneimittel-Forsch. 33 (1983) 627–631.
- 86 A. Peretz et al. Mol. Pharmacol. 67 (2005) 1053–1066.
- 87 Y. T. Lee, Q. Wang, Eur. J. Pharmacol. 378 (1999) 349–356.
- 88 Parke Davis, US 3 138 636, 1964; DE 1 163 846, 1961.
- 89 G. R. Singh, P. Choudhury, Indian Pediatr. 26 (1989) 577–579.
- 90 M. Ottolia, L. Toro, Biophys. J. 67 (1994) 2272–2279.
- 91 J. S. Marks, M. H. Gleeson, Br. Med. J. 4 (1975) 442.
- 92 Labs. U.P.S.A., US 3 415 834, 1968; US 3 337 570, 1967.
- 93 J. Auclair et al., Curr. Ther. Res. 46 (1989) 782–788.
- 94 M. Civelli et al., Agents Actions 33 (1991) 233–239.
- 95 Park Davis, US 3313848 (A. Scherer, F. W. Short), 1967
- 96 M. Zovko, B. Zorc, M. J.-M. Takac, B. Metelko, P. Novac, Croatica Chemica Acta 76 (2003), 335–341.
- 97
T. Corell,
Pharmacol. Toxicol. 75 Suppl
2
(1994)
14–21.
10.1111/j.1600-0773.1994.tb01991.x Google Scholar
- 98
H. Isomaki,
Pharmacol. Toxicol. 75 Suppl
2
(1994)
64–65.
10.1111/j.1600-0773.1994.tb02001.x Google Scholar
- 99
J. Delgado et al.
Pharmacol. Toxicol. 75 Suppl
2
(1994)
89–91.
10.1111/j.1600-0773.1994.tb02008.x Google Scholar
- 100
P. E. Hansen,
Pharmacol. Toxicol. 75 Suppl
2
(1994)
81–82.
10.1111/j.1600-0773.1994.tb02005.x Google Scholar
- 101 K. H. Boltze et al., Arzneim.-Forsch./Drug Res. 30 (1977) no. 2 1314–1325.
- 102 H. Jacobi, H. D. Dell, Arzneimittel-Forsch. 30 (1980) 1348–1362.
- 103 Rotta Research Lab., DOS 2 535 799, 1975.
- 104 Rotta Research Lab., US 3 985 878, 1974.
- 105 F. Makovec et al., Arzneimittelforschung 37 (1987) 806–813.
- 106 V. Fossaluzza et al., Minerva Med. 74 (1983) 723–726.
- 107 N. P. Buu-Hoi et al., Hebd. Seances Acad. Sci. 261 (1965) 2259.
- 108 P. Moser et al., J. Med. Chem. 33 (1990) 2358–2368. Link
- 109 P. A. Todd, E. M. Sorkin, Drugs 35 (1988) 244–285.
- 110 T. Y. Shen et al., J. Am. Chem. Soc. 85 (1963) 488–489.
- 111 Merck & Co., US 3 161 654, 1964, DE 1 232 150, 1962.
- 112 H. Yamamoto et al., Chem. Pharm Bull. 16 (1968) no. 17, 647.
- 113 Byk Gulden, US 4 4 325 962, 1982; DE 1 946 370, 1969.
- 114 G. Rainer et al., Arzneim.-Forsch./Drug Res. 31 (1981) 649–655.
- 115
B. Unterhalt,
Drugs Future
7
(1982)
110–111.
10.1358/dof.1982.007.02.199340 Google Scholar
- 116 Merck & Co., US 3 882 239, 1975; DE 1 039 426, 1970.
- 117 R. F. Shuman et al., J. Org. Chem. 42 (1977) 1914–1919.
- 118 R. N. Brogden et al., Drugs 16 (1987) 97–114.
- 119 A. Whelton et al., JAMA 249 (1983) 2892.
- 120 T. D. Warner et al., Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 7563–7568.
- 121 C. Haanen, Curr. Opin. Investig. Drugs 2 (2001) 677–683
- 122 McNeil, US 3 752 826, 1973; GB 1 428 272, 1973.
- 123 J. R. Carson et al., J. Med. Chem. 14 (1971) 646–647.
- 124 R. N. Brogden, Drugs 15 (1978) 429–450.
- 125 C. Brideau et al., Inflamm Res. 45 (1996) 68–74.
- 126
E. Arrigoni-Martelli,
J. Prous,
J. Castaner,
Drugs of the Future
14
(1989)
963.
10.1358/dof.1989.014.10.109633 Google Scholar
- 127 G. Biasi, R. Marcolongo, Minerva Med. 92 (2001) 315–324.
- 128 G. Coruzzi et al., Curr. Drug Targets Inflamm. Allergy. 3 (2004) 43–61.
- 129 G. Coruzzi et al., Dig. Liver Dis. 34 (2002) 403–410.
- 130
J. Prous,
J. Castaner,
Drugs of the Future
13
(1988)
1050.
10.1358/dof.1988.013.12.77459 Google Scholar
- 131 CDC Life Sciences Inc., US 4 327 222, 1982 (R. G. Micetich et al.).
- 132 Teiho Pharmaceuticals, EP 454 871, 1990 (H. Tanaka, Y. Hagiwara, H. Kajitani, H. Yasumoto).
- 133 Taiho Pharmaceuticals, EP 464 218, 1991 (H. Tanaka, Y. Hagiwara, H. Kajitani, H. Yasumoto).
- 134 CDC Life Science, EP 26928, 1981 (R. G. Micetich et al.).
- 135 T. Ushio et al, Iykuhin Kenkyu 22 (1991) 892.
- 136 N. Ono et al., Nippon Yakurigaku Zasshi. 95 (1990) 63–81.
- 137 K. Goto et al., Prostaglandins Other Lipid Mediat. 56 (1998) 245–254.
- 138 D. A. Walch et al., J. Med. Chem. 27 (1984) 1379–1388.
- 139 US 4 126 635, 1977 (H. Robins et al.).
- 140 A.H. Robinson Co., Inc. US 4 568 695, 1983 (H. Robins et al.).
- 141
J. Prous,
J. Castaner,
Drugs of the Future
13
(1988)
943.
10.1358/dof.1988.013.11.66932 Google Scholar
- 142 T. Ogawa et al. Nippon Ganka Gakkai Zasshi 99 (1995) 406–411.
- 143 R. J. Fontana et al., Liver Transpl. Surg. 5 (1999) 480–484.
- 144 E. B. Hunter et al., Am. J. Gastroenterol. 94 (1999) 2299–2301.
- 145 P. L. Moses et al., Am. J. Gastroenterol. 94 (1999) 1393–1396.
- 146 Beecham, US 4 420 639, 1983; DE 2 463 219, 1974.
- 147 A. C. Goudie et al., J. Med. Chem. 12 (1978) 1260–1264.
- 148
M. Neumann,
Drugs Future
6
(1981)
35–36.
10.1358/dof.1981.006.01.49326 Google Scholar
- 149 C. Prabhakar et al., Org. Process Res. Dev. 3 (1999) 121–125.
- 150 H. A. Friedel et al., Drugs 45 (1993) 131–156.
- 151 Degussa, US 3 513 171, 1970; DE 1 670 522, 1966.
- 152
Drugs Future
8
(1983)
773–775.
10.1358/dof.1983.008.09.53539 Google Scholar
- 153 W. v. Bebenburg, et al., Chem. Ztg. 105 (1981) 217–219.
- 154 W. v. Bebenburg, G. Steinmetz, K. Thiele, Chem. Ztg. 103 (1979) 387–399.
- 155 M. L. Brochier, Eur. Heart J. 14 (1993) 951–957.
- 156 W. J. Wechter et al., Cancer Res. 60 (2000) 2203–2208.
- 157 J. M. Mayer, B. Testa, Drugs Future 22 (1997) 1347–1366.
- 158 M. Cleij et al., J. Org. Chem. 64 (1999) 5029–5035.
- 159 M. Busson, J. Int. Med. Res. 14 (1986) 53–62.
- 160 Rhône-Poulence, US 3 641 127, 1972.
- 161 G. G. Liversidge, Anal. Profiles Drug Subst. 10 (1981) 443–471.
- 162 J. L. Hommeril et al., Br. J. Anaesth. 72 (1994) 383–387.
- 163 P. Patrignani et al., J Physiol. Pharmacol. 48 (1997) 623–631.
- 164 R. L. Dorfman, Arzneim.-Forsch./Drug Res. 25 (1975) 278–281.
- 165 T. Y. Shen, Angew. Chem. Int. Ed. Engl. 11 (1972) 460.
- 166 H. R. Bellur, J. R. Ahuja, D. G. Kulkarni, Tetrahedron: Asymmetry 3 (1992) 163–192.
- 167 Syntex, US 3 663 584, 1972.
- 168 Syntex, US 4 605 758, 1986.
- 169 P. A. Todd, S. P. Clissold, Drugs 40 (1990) 91–137.
- 170 J. Rautio et al., J. Med. Chem. 43 (2000) 1489–1494.
- 171 Roussel-Uclaf, DOS 2 055 264, 1970.
- 172 G. L. Plosker, A. J. Wagstaff, Drugs 50 (1995) 1050–1075.
- 173 F. G. Mayall et al., Br. Med. J. 309 (1994) 599–600.
- 174 J. Prous, J. Castaner, Drugs of the Future 14 (1989) 302.
- 175 Nippon Chemiphar, US 4 247 706, 1981 (Y. Fujimoto, S. Yamabe).
- 176 M. Hatori, S. Kokubun, Curr. Med. Res. Opin. 14 (1998) 79–87.
- 177 N. Murakami et al., Jpn. J. Pharmacol. 72 (1996) 29–37.
- 178 H. B. Tang et al., Neuropharmacology 48 (2005) 1035–1042.
- 179 R. W. Carney et al., Experientia 29 (1973), 938.
- 180 Ciba, US 3 641 040, 1972 (R. W. Carney, G. DeStevens).
- 181 P. A. Todd, R. Beresford, Drugs. 32 (1986) 509–537.
- 182 M. Guidotti et al., J. Int. Med Res. 17 (1989) 48–54.
- 183 J. Pirotte et al., Gastroenterol. Clin. Biol. 11 (1987) 520.
- 184 J. R. Hannequin et al., Rev. Rheum. Mal. Osteoartic. 55 (1988) 983–988.
- 185 A. C. Depla et al., Neth. J. Med. 37 (1990) 32–36.
- 186 M. Eugene et al., Rev. Med. Interna 8 (1987) 115.
- 187 Ely Lilly, DOS 1 941 625, 1969.
- 188 Ely Lilly, US 3 600 437, 1971 (W. S. Marshall).
- 189 Mitsubishi Petrochemical, DOS 2 646 792, 1976 (M. Takeda, M. Uchide, H. Masayuka).
- 190 Nissin Flour Milling, US 4 016 196, 1977 (K. Katsura Kogure, T. Noriyoshi Sueda, T. Youziro Yoshino, K. Kunio Nakagawa).
- 191 Sagami, DAS 2 709 504, 1977 (G. Tsuchihashi, K. Ogura).
- 192 C. M. Gruber Jr., J. Rheumatol. 2 (1976) 8–17.
- 193 R. N. Brogden et al., Drugs 13 (1977) 241–265.
- 194 R. N. Brogden et al., Drugs 21 (1981) 1–22.
- 195 J. R. Ryan et al., Clin. Pharmacol. Ther. 42 (1987) 28–32.
- 196 M. L. Wendland et al., Mayo Clin. Proc. 55 (1980) 103–107.
- 197 J. S. Stotts et al., J. Am. Acad. Dermatol. 18(4 Pt 1) (1988) 755–757.
- 198 CERM, US 4 218 473, 1980 (J. J. Godfroid, E. Steiner).
- 199 M. Hoeijmakers et al., J. Vet. Pharmacol. Ther. 28 (2005) 305–312.
- 200 T. Nell et al., J. Small Anim. Pract. 43 (2002) 208–212.
- 201 P. Lees et al., J. Vet. Pharmacol. Ther. 22 (1999) 96–106.
- 202 D. A. Walsh et al., J. Med. Chem. 33 (1990), 2296–2304.
- 203 Alcon, WO 09932104, 2000 (J. H. Yanni, M. R. Hellberg).
- 204 T. L. Ke et al., Inflammation 24 (2000) 371–384.
- 205 K. Takahashi et al., Invest. Ophthalmol. Vis. Sci. 44 (2003) 409–415.
- 206 D. A. Gamache et al., Inflammation 24 (2000) 357.
- 207 R. Linstrom, T. Kim, Curr. Med. Res. Opin. 22 (2006) 397–404.
- 208 W. J. Welstead et al., J. Med. Chem. 22 (1979), 1074–1079.
- 209 Robins Co., Inc., DE 2 324 768, 1973 (W. Welstead, H. W. Moran)
- 210 Robins Co., Inc., US 1972 254 285, 1972 (W. Welstead, H. W. Moran)
- 211 G. Ehrhart, H. Ruschig: Arzneimittel, Entwicklung, Wirkung, Darstellung, vol. 1, Verlag Chemie, Weinheim 1972, pp. 171–172.
- 212 I.G. Farben, DRP 476 663, 1922.
- 213 Z. Fendrich, Cas. Lek. Cesk. 139 (2000) 440–444.
- 214 F. Arellano, J A. Sacristan, Eur. J. Clin. Pharmacol. 38 (1990) 617–619.
- 215 M. Levy et al., Clin. Pharmacokinet. 28 (1995) 216–234.
- 216 Hoffmann-La Roche, DRP 565 799, 1931.
- 217 Riedel-deHaen, DE 962 254, 1954.
- 218 K. Brune, Agents Actions 25 Suppl. (1988) 9–19.
- 219 E. Gores et al., Med. Monatsschr. Pharm. 27 (2004) 72–76.
- 220 R. Denss et al., Helv. Chim. Acta 40 (1957) 402.
- 221 M. Kühn et al., J. Prakt. Chem. 156 (1940) 103.
- 222 Horakova et al., Pharmacotherapeutica (1963) 335–350.
- 223 J. Büchi et al., Helv. Chim. Acta 36 (1953) 75.
- 224 Comm. Farmaceutica Milanese, GB 839 057, 1957.
- 225 D. Loew et al., Z. Rheumatol. 44 (1985) 186–192.
- 226 Geigi, US 2 745 783, 1956.
- 227 L. E. Westerholm, Br. Med. J. 3 (1973) 339–343.
- 228 Geigi, US 2 562 830, 1951.
- 229 S. L. Ali, Anal. Profiles Drug Subs. 11 (1982) 483–521.
- 230 G. A. Faich, Pharmacotherapy 7 (1987) 25–27.
- 231 Warner-Lambert, DOS 2 208 351, 1972.
- 232 J. G. Lombardino, E. H. Wisemann, J. Med. Chem. 14 (1971) 973.
- 233 H. Zinnes et al., J. Med. Chem. 25 (1982) 12.
- 234 W. W. Downie, Semin. Arthritis Rheum. 12 (1982) Suppl. 2, 170–174.
- 235
Drugs Future
17
(1992)
683–686.
10.1358/dof.1992.017.08.179585 Google Scholar
- 236 T. Pruss et al., Postgrad. Med. J. 66 (1990) Suppl. 4818–821.
- 237 T. Christoph et al., Inflamm. Res. 44 (1995) Suppl. 3 Abstr. W16/17.
- 238 J. A. Balfour et al., Drugs 51 (1996) 639–657.
- 239 Pfizer, US 3 591 584, 1971; US 4 469 866, 1984.
- 240 J. G. Lombardino et al., J. Chiaini, J. Med. Chem. 5 (1973) 493–496.
- 241 E. H. Wisemann et al., Arzneim.-Forsch./Drug Res. 26 (1976) 1300–1303.
- 242
L. Castaner,
E. Arrigoni-Martelli,
Drugs Future
2
(1977)
124–127.
10.1358/dof.1977.002.02.612399 Google Scholar
- 243 Hoffmann-La Roche, DOS 2 537 070, 1975.
- 244 R. N. Brogden et al., Drugs 22 (1981) 165–187.
- 245 R. N. Brogden et al., Drugs 28 (1984) 292–323.
- 246 J. A. Mitchell et al., Proc. Natl. Acad. Sci. USA 90 (1993) 11693–11697.
- 247
E. Arrigoni-Martelli,
Drugs Future
7
(1982)
493–494.
10.1358/dof.1982.007.07.49382 Google Scholar
- 248 P. A. Todd, S. P. Clissold, Drugs 41 (1991) 625–646.
- 249 Synthex, US 4 347 186, 1982; US 4 458 081, 1984; US 4 873 340, 1989.
- 250
E. Arrigoni-Martelli,
Drugs Future
8
(1983)
871–874.
10.1358/dof.1983.008.10.61883 Google Scholar
- 251 A. Guzman et al., J. Med. Chem. 29 (1986) 589–591.
- 252 J. M. Muchowski et al., J. Med. Chem. 28 (1985) 1037–1049.
- 253 F. F. Franco et al., J. Org. Chem. 47 (1982) 1682–1688.
- 254 M. M. T. Buckley, R. N. Brogden, Drugs 39 (1990) 86–109.
- 255 John Wyeth and Brothers, Ltd, US 3578671, 1971 (K. Brown).
- 256
E. Arrigoni-Martelli,
Drugs of the Future
3
(1978)
539–542.
10.1358/dof.1978.003.07.201757 Google Scholar
- 257 L. G. Miller, Clin. Pharm. 11 (1992) 591–603.
- 258 American Home Products, US 3 843 681, 1974.
- 259
L. Castaner,
E. Arrigoni-Martelli,
Drugs Future
2
(1977)
21–23.
10.1358/dof.1977.002.01.49311 Google Scholar
- 260 C. A. Demerson, et al., J. Med. Chem. 19 (1976) 391–395.
- 261 C. A. Demerson et al., J. Med. Chem. 18 (1975) 189.
- 262 N. Bellamy, Inflammopharmacology 5 (1997) 139–152.
- 263 A. S. Taha et al., Gut 30 (1989) A751.
- 264 G. Bianchi Porro, et al., J. Intern. Med. 229 (1991) 5–8.
- 265 Thomae GmbH, DE 2 756 113, 1979.
- 266
G. Trummlitz,
G. Engelhardt,
U. Busch,
Drugs Future
14
(1989)
1047–1048.
10.1358/dof.1989.014.11.109638 Google Scholar
- 267 G. Engelhardt et al., Inflamm. Res. 44 (1995) 423–433.
- 268 J. A. Lopez-Garcia et al., Neuroreport 9 (1998) 647–651.
- 269 Riker, US 3 840 597, 1974; DOS 2 333 643, 1973.
- 270 R. Davis, R. N. Brogden, Drugs 48 (1994) 431–454.
- 271 A. Azab et al., Life Sci. 63 (1998) PL 323–327.
- 272 P. A. McCormick et al., Lancet 353 (1999) 40–41.
- 273 C. Ferreiro et al., Gastroenterol. Hepatol. 23 (2000) 428–430.
- 274 G. Steinbach et al., N. Engl. J. Med. 342 (2000) 1946–1952.
- 275 J. L. Goldstein et al., Am. J. Gastroenterol. 96 (2001) 1019–1027
- 276 F. E. Silverstein et al., JAMA 284 (2000) 1247–1255.
- 277 J. M. Brophy, Expert Opin. Drug. Saf. 4 (2005) 1005–1015.
- 278 L.A. Sorbera et al., Drugs of the Future 26 (2001) 346–353.
- 279 R.W. Friesen et al., Biorg. Med. Chem. Lett. 8 (1999) 2777–2782.
- 280 I. W. Davies et al., J. Org. Chem. 65 (2000) 8415–8420.
- 281 I. W. Davies et al., J. Org. Chem. 65 (2000) 8571–8574.
- 282 J. F. Marcoux et al., Org. Lett. 2 (2000) 2339–2341.
- 283 A. Dallob et al., J Clin Pharmacol. 43 (2003) 573–585.
- 284 D. J. Cochrane et al., Drugs. 62 (2002) 2637–2651.
- 285 A. D. Rodrigues et al., Drug Metab. Dispos. 31 (2003) 224–232.
- 286 K. Kassahun et al., Drug Metab. Dispos. 29 (2001) 813–820.
- 287 N. Chauret et al., Bioorg. Med. Chem. Lett. 11 (2001) 1059–1062.
- 288 D. R. Ramey et al., Curr. Med. Res. Opin. 21 (2005) 715–722.
- 289 S. P. Curtis et al., Clin Ther. 26 (2004) 70–83.
- 290 S. Aldington et al., N. Z. Med. J. 118 (2005) U1684.
- 291 Novartis, WO 2001 023346, 2001 (M. Murat, T. Allemendiger, J. Calienni, J. Cercus, O. Loiseleur).
- 292 Novartis, WO 1999 011605, 1999 (L. Mcquire, B. Mugrage, J. Van Duzer).
- 293 K. A. Lyseng-Williamson et al., Drugs 64 (2004) 2237–2246.
- 294 F. Berenbaum et al., J. Int. Med. Res. 33 (2005) 21–41.
- 295 P. Geusens et al., Int. J. Clin. Pract. 58 (2004) 1033–1041.
- 296 E. Packman et al., Headache 45 (2005) 1163–1170.
- 297 J. A. Rosenberg et al., Nat. Clin. Pract. Gastroenterol. Hepatol. 2 (2005) 14–15.
- 298 C. J. Hawkey et al., Clin. Gastroenterol. Hepatol. 4 (2006) 57–66.
- 299 P. Matchaba et al., Clin. Ther. 27 (2005) 1196–214.
- 300 H. Tannenbaum et al., Ann. Rheum. Dis. 63 (2004) 1419–1426.
- 301 C. M. Rordorf et al., Clin. Pharmacokinet. 44 (2005) 1247–1266.
- 302 J. J. Talley et al., J. Med. Chem. 43 (2000) 1661–1663.
- 303 Searle & Co. WO 9515316; US 5 521 207; EP 731 795 1995 (J. J -Talley et al.).
- 304 C. D. Furberg et al., Circulation 111 (2005) 249.
- 305 E. G. Harks et al., J. Pharmacol. Exp. Ther. 298 (2001) 1033–1041.
- 306 L. A. Sorbera et al. Drugs Future 23 (1998) 1287–1296.
- 307 M. Therien et al., Synthesis (2001) 1778–1779.
- 308 L. J. Scott, H. M. Lamb Drugs. 58 (1999) 499–505.
- 309 A. J. Matheson, D. P. Figgitt, Drugs. 61 (2001) 833–865.
- 310 C. C. Chan et al., J. Pharmacol. Exp. Ther. 290 (1999) 551–560.
- 311 L. Laine et al., Gastroenterology 117 (1999) 776–783.
- 312 C. Bombardier et al., N. Engl. J. Med. 343 (2000) 1520–1528.
- 313 M. Wadman, Nature 433 (2005) 790.
- 314 J. J. Talley in F. D. King A. W. Oxford (eds.): Progress in Medicinal Chemistry-Vol 36, Elsevier, Amsterdam 1999.
- 315 D. Ormrod et al., Drugs 62 (2002) 2059–2071.
- 316 M. L. Chavez, C. J. De Korte Clin Ther. 25 (2003) 817–851.
- 317 C. Fenton et al. Drugs. 64 (2004) 1231–1261.
- 318 J. E. Edwards et al. Pain 111 (2004) 286–296.
- 319 G. P.Joshi Expert Rev. Neurother. 5 (2005) 11–24.
- 320 D. Kudrow et al. Headache 45 (2005) 1151–1162.
- 321 C. Talhari et al., J. Allergy Clin. Immunol. 115 (2005) 1089–1090.
- 322 F. L. Byerly et al., Burns 31 (2005) 383–387.
- 323 N. A. Nussmeier et al. N. Engl. J. Med. 352 (2005) 1081–1091.
- 324 T. E. Egan, Clin. Pharmacokinet. 29 (1995) 80–94.
- 325 Janssen, US 3 998 834, 1976.
- 326 E. M. Schultz et al., J. Am. Chem. Soc. 69 (1947) 2454–2459.
- 327 B. Kögel et al. Eur. J. Pain. 9 (2005) 599–611.
Further Reading
- J. K. Aronson: Meyler's Side Effects of Analgesics and Anti-inflammatory Drugs, Elsevier, Amsterdam 2010.
- P. Beaulieu, D. Lussier, F. Porreca, A. Dickenson: Pharmacology of Pain, IASP Press, Seattle 2010.
-
H. Buschmann et al.:
Analgesics-From Chemistry and Pharmacology to Clinical Application,
Wiley-VCH,
Weinheim
2002.
10.1002/3527605614 Google Scholar
- S. M. Fishman, J. C. Ballantyne, J. P. Rathmell (eds.): Bonica's Management of Pain, 4th ed., Lippincott Williams & Wilkins, Philadelphia 2009.
- E. Freye: Opioids in Medicine, Springer, Dordrecht 2008.
